Handbook of Cannabis and Related Pathologies

Handbook of Cannabis and Related Pathologies

Biology, Pharmacology, Diagnosis, and Treatment
2017, Pages 958-967
Handbook of Cannabis and Related Pathologies

Chapter 99 - Potential Medical Uses of Cannabigerol: A Brief Overview

https://doi.org/10.1016/B978-0-12-800756-3.00115-0Get rights and content

Abstract

After the description of its chemical structure and synthesis in 1964, research on cannabigerol (CBG) progressed slowly, mainly due to its low concentration in the Cannabis plant. In fact, CBG is rapidly converted into its metabolites tetrahydrocannabinol (THC), cannabichromene (CBC), and cannabidiol (CBD). In recent years, a constellation of studies shone light onto CBG’s pharmacology and its potential medical applications. Literature highlights its numerous pharmacological properties ranging from adrenergic, serotoninergic, cannabinergic and transient receptor potential (TRP) actions, to the modulation of enzymes, such as cyclooxygenase, monoacyl glycerol lipase (MAGL), N-acylethanolamine acid amidase (NAAA) and phospholipase-A2 (PLA2). Possible medical applications of CBG found voice in several scientific publications some of which inspired the initiation of patents to protect its therapeutic uses. Current literature offers evidence of its potentials as an antiinflammatory and anticancer agent, to only cite a few, addressing interest on this phytocannabinoid as a potential starting material for new therapeutic agents. CBG owns a broad pharmacological activity, and the knowledge of its precise mechanism of action, as well as its still unknown clinical efficacy and possible adverse effects would unquestionably benefit from further research.

References (0)

Cited by (22)

  • Cannabis: Chemistry, extraction and therapeutic applications

    2022, Chemosphere
    Citation Excerpt :

    Unlike CBGA, CBG does not undergo any catalytic conversion into other cannabinoids due to the absence of the carboxyl group (–COOH) (Taura et al., 2007). CBG is effective in the treatment of inflammatory bowel disease, bladder dysfunction, Huntington's disease, tumors and certain types of cancers in animal studies (Borrelli et al., 2013; Valdeolivas et al., 2015; Pagano et al., 2015; Deiana, 2017). Furthermore, CBG shows several instances of anti-bacterial activities and has been tested on relieving muscle contractions.

  • Industrial hemp breeding and genetics

    2022, Industrial Hemp: Food and Nutraceutical Applications
  • Anticancer agents based on Plastoquinone analogs with N-phenylpiperazine: Structure-activity relationship and mechanism of action in breast cancer cells

    2021, Chemico-Biological Interactions
    Citation Excerpt :

    Their role in apoptosis, cell cycle arrest, and cell migration, etc. has also been well studied [42]. Natural cannabinoids [43], their metabolites [44], and synthetic cannabinoid analogs [45] have also been reported to have antiproliferative activity. Considering the structural similarity of PQ11 with HU331 and its activity profile, we hypothesize that the putative target for PQ11 could be CB2.

View all citing articles on Scopus
View full text